INSERM, U1015, Institut Gustave Roussy, Villejuif, France.
Cancer Res. 2010 Dec 1;70(23):9538-43. doi: 10.1158/0008-5472.CAN-10-1003. Epub 2010 Nov 23.
Current cancer management aims to integrate molecular signatures into the design of personalized therapies. Recent advances in "omics" done on tumor specimens have led to the identification of factors that either recognize cancers of dismal prognosis or pinpoint "druggable" signaling pathways, which can be interrupted by targeted therapies. However, accumulating evidence underscores the biological and clinical significance of immune predictors in several compartments (blood, serum, tumor) in a variety of malignancies. An additional aspect that has been overlooked is the bidirectional, tumor-host interaction during therapeutic intervention, suggesting that dynamic molecular, biochemical, and metabolic signatures should be developed in the future. We review immune parameters of prognostic or predictive value during cancer therapy, and highlight existing "descriptive-prognostic" and "functional-therapeutic" molecular signatures, with the hindsight of designing appropriate compensatory therapies.
目前的癌症治疗旨在将分子特征整合到个性化治疗的设计中。最近在肿瘤标本上进行的“组学”研究取得了进展，确定了识别预后不良的癌症或确定可通过靶向治疗干预的“可治疗”信号通路的因素。然而，越来越多的证据强调了免疫预测因子在多种恶性肿瘤的几个部位（血液、血清、肿瘤）中的生物学和临床意义。另一个被忽视的方面是治疗干预过程中肿瘤-宿主的双向相互作用，这表明未来应该开发动态的分子、生化和代谢特征。我们回顾了癌症治疗过程中具有预后或预测价值的免疫参数，并强调了现有的“描述性-预后”和“功能性-治疗”分子特征，为设计适当的补偿性治疗提供了参考。
